Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{170932,
        author = {Thillainayagi M. and R. Bharathidasan and G Thiruneelakandan},
        title = {Studies on Anti-colon cancer of Marine Lactobacillus helveticus protein},
        journal = {International Journal of Innovative Research in Technology},
        year = {2024},
        volume = {11},
        number = {7},
        pages = {3511-3518},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=170932},
        abstract = {One of the world's most deadly diseases is still cancer. There were approximately 10 million deaths every year. Chemotherapy has been associated with numerous adverse effects, despite significant advances in treatment. Thereby encouraging the search for a different, less harmful treatment option. The marine environment was used to isolate the lactobacilli strains. In order to conduct in-vivo research anti-colon cell line models, the crude protein was extracted from the bacteria and used as an anticancer medication.  At 24 hours of growth, L. helveticus had the highest free radical scavenging activity (1,1-diphenyl-2-picrylhydrazyl), but this activity significantly decreased at 48 hours when compared to the other strains and the control. Throughout the growth period, L. helveticus strains contained compounds with anti-colon cancer activity.  After 24 hours of growth, the extract with the highest activity (19.03–50.98% inhibition of growth) significantly decreased (5.4–9.94%) at the end of the growth period. When compared to the other strains, Lactobacillus helveticus produced compounds that inhibited the growth of the colon cancer HT-29 cell line by 50.98 percent in the culture supernatant after 48 hours. More importantly, T4056 normal primary colon cells were not significantly inhibited by these compounds. These findings, on the other hand, suggested that L. helveticus strains might release bioactive compounds with important properties that can serve multiple purposes.},
        keywords = {Lactobacillus helveticus, colon cancer, HT-29 cell line, T4056.},
        month = {December},
        }